▎WuXiEdited by Kant Content Team

Today, Ipsen and Marengo Therapeutics announced the expansion of their ongoing early-stage oncology research collaboration, which includes adding two additional collaborative pipelines and utilizing Marengo's next-generation precision T-cell engager (TCE) technology, the TriSTAR platform, with a potential total transaction value of $1.2 billion.

Traditional TCEDue to the poor quality and exhaustion of T cells in patients, the effect on "cold" tumors that respond poorly to immunotherapy is limited.MarengoProprietary "first-in-class"The TriSTAR platform is a multispecific antibody fusion platform derived from Marengo Therapeutics' proprietary antibody library, which targets different T cell receptor (TCR) Vβ variants and is fused with T cell costimulatory receptors and tumor-associated antigen binders.By expanding and redirecting a new, highly active memory Vβ T-cell poolTo the tumorTriSTAR TCE may overcome factors that limit the activity of traditional TCE, including poor T cell quality and T cell exhaustion.

According to the terms of the agreement, Ipsen will be responsible forCandidate DrugAfter NominationAllDevelopmentActivity.Marengo Therapeutics will receive an upfront payment and other potential payments, with the total amount reaching up to $1.2 billion if all milestones are achieved.

In August 2022, Ipsen and Marengo Therapeutics reached a potential total of approximately $1.6 billionStrategic Cooperation, jointly utilizing Marengo Therapeutics' STAR multispecific fusion protein technology platform to advance two preclinical selective TCR activators into clinical trials.

References:

[1] Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platform. Retrieved June 7, 2024 from https://www.ipsen.com/press-releases/ipsen-and-marengo-therapeutics-announce-second-strategic-partnership-to-advance-precision-t-cell-engagers-from-marengos-tri-star-platform/

Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange purposes only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it indicate that WuXi AppTec supports or opposes these views. This article is not a recommendation for treatment plans. If you need guidance on treatment options, please visit a正规 hospital.

Copyright Statement: This article is from the content team of WuXi AppTec. Individuals are welcome to share it on their social media platforms, but unauthorized reproduction by media or institutions in any form on other platforms is prohibited. For authorization to reproduce, please reply with "reprint" on the WeChat Official Account of "WuXi AppTec" to obtain reprint guidelines.